Solventum Corporation
SOLV Healthcare Medical Instruments & Supplies
Solventum Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.86% from fiscal 2024. In the quarter to June 2026, revenue grew 2.22%, EPS grew 1.92%, free cash flow grew 144.1% and total debt fell 32.4%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years; insiders bought in the last twelve months.
Follow SOLV
Solventum Corporation (SOLV) EBITDA
Solventum Corporation's EBITDA for fiscal 2025 was $2.7B, up 67.8% from $1.6B in fiscal 2024. Over the twelve months to 30 June 2026 it was $2.6B. Solventum Corporation ranks 5th of 50 Medical Instruments & Supplies companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $2.7B | 67.82% |
| FY2024 | $1.6B | (29.38%) |
| FY2023 | $2.3B | (0.79%) |
| FY2022 | $2.3B | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $314.0M | 46.05% |
| Mar 2026 | $215.0M | (11.16%) |
| Dec 2025 | $242.0M | (86.64%) |
| Sep 2025 | $1.8B | 438.99% |
| 10 more quarters | Free account |
EBITDA against peers
| Company | EBITDA |
|---|---|
| ALC Alcon compare | $2.7B |
| SOLV Solventum Corporation | $2.6B |
| BAX Baxter International Inc. compare | $1.5B |
| COO The Cooper Companies, Inc. compare | $928.2M |
| WST West Pharmaceutical Services, Inc. compare | $861.8M |
| ALGN Align Technology, Inc. compare | $802.0M |
| ATR AptarGroup, Inc. compare | $784.6M |
| RGEN Repligen Corporation compare | $161.0M |
| AVTR Avantor, Inc. compare | $124.8M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on SOLV
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement